Release Date: April 27, 2017

Expiration Date: April 27, 2018


Target Audience

This CME-certified educational activity is designed for healthcare professionals treating patients with Duchenne Muscular Dystrophy.


Program Overview

Within the last four decades, the evolving natural history of Duchenne Muscular Dystrophy (DMD) continues to affect both survival and the loss of clinically meaningful motor functions. Various medical interventions such as the efficacious use of corticosteroids and genetic alteration of the dystrophin gene have impacted the insidious course of this disease's progression and quality-of-life issues by measurably prolonging the duration of muscular capacity.


In recent years, advances in medical research and a better understanding of the pathophysiology of DMD have allowed the development of novel agents and improved treatment strategies for patients that were left previously with minimal therapeutic options. This CME activity will examine the typical and ameliorated natural history of DMD, instruments for surveillance of clinical course, and administration of medicines with proven efficacy for individual patients. Equally important, expert faculty will address an explanation of the data necessary to prove medical necessity to health insurance providers and empower families to work with insurers.


Educational Objectives

After completing this CME activity, the participant will be able to:

  1. Discuss the natural history of DMD and the factors that can facilitate early diagnosis and treatment.
  2. Evaluate the prevailing evidence surrounding how genetic testing can inform the direction of clinical research in treating neuromuscular degeneration.
  3. Recognize important criteria documented in the 2016 AAN evidence-based guidelines for the management of DMD using currently available treatment options.
  4. Contrast current and emerging therapies for DMD to demonstrate how different therapies can be used to individualize patient care.
  5. Discuss endpoints for measuring clinical course in patients with DMD and the challenges of demonstrating necessity of treatment for reimbursement.


Physician Accreditation Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and HealthmattersCME.  Global is accredited by the ACCME to provide continuing medical education for physicians.


Physician Credit Designation

Global Education Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 Credits™.  Physicians should claim only the credit commensurate with the extent of their participation in the activity.


Nursing Accreditation Statement

Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center's Commission on Accreditation.


Nursing Credit Designation

This educational activity for 1.0 contact hour is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.

Global Contact Information

For information about the accreditation of this program, please contact Global at 303-395-1782 or

Fee Information& Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosure of Conflicts of Interest

Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Name of Faculty or Presenter

Reported Financial Relationship

John W. Day, MD, PhD

Grants/Research Support: AveXis, Biogen, Cytokinetics, Genzyme Biotechnology Corporation, Ionis Pharmaceuticals, Sarepta Therapeutics


Consulting: AveXis, Biogen, Cytokinetics, Sarepta Therapeutics


Royalties for Licensed Technology: Athena Diagnostics

Perry B. Shieh, MD, PhD

Consultant/Independent Contractor: AveXis, Biogen, Genentech, Marathon Pharmaceuticals, PTC Therapeutics, Sarepta Therapeutics

Grants/Research Support: Bristol-Myers Squibb, Catabasis, FibroGen, Pfizer, PTC Therapeutics, Sarepta Therapeutics, Summit

Speaker: Grifols


The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:


Name of Planner or Manager

Reported Financial Relationship

Andrea Funk

Nothing to disclose

Laura Gilsdorf

Nothing to disclose

Ashley Marositca, RN, MSN

Nothing to disclose

James Murphy

Nothing to disclose


Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and HealthmattersCME do not recommend the use of any agent outside of the labeled indications. 


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.



Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.



This activity was released on April 27, 2017 and is valid for one year. Requests for credit must be made no later than April 27, 2018.



In order to receive credit for this activity, the participant must complete the online post-test, with a passing score of 70% or higher, and the online evaluation form.



Supported Browsers:

Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8

Google Chrome 28.0+ for Windows, Mac OS, or Linux

Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux

Safari 5.0+ for Mac OSX 10.5 and above

For video playback, install the latest version of Flash


This activity is jointly provided by Global Education Group and HealthmattersCME.


This activity is supported by an independent educational grant from Sarepta Therapeutics.



Acknowledge and Proceed